Gene:
F3
coagulation factor III (thromboplastin, tissue factor)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs3917643 10547A>G, 213-147A>G, 64973785T>C, 95001867T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs841698 64990437T>C, 95018519T>C
T > C
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  CD142
PharmGKB Accession Id: PA158

Details

Cytogenetic Location: chr1 : p21.3 - p21.3
GP mRNA Boundary: chr1 : 94994732 - 95007413
GP Gene Boundary: chr1 : 94991732 - 95017413
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Extrinsic Pathway - (Reactome via Pathway Interaction Database)
  2. extrinsic prothrombin activation pathway - (BioCarta via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
simvastatin

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Myocardial Ischemia

Publications related to F3: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping. The pharmacogenomics journal. 2011. Matsson P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease. Atherosclerosis. 2009. Undas Anetta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. The Journal of experimental medicine. 2007. Ghosh Mallika, et al. PubMed

LinkOuts

Entrez Gene:
2152
OMIM:
134390
UCSC Genome Browser:
NM_001993
RefSeq RNA:
NM_001178096
NM_001993
RefSeq Protein:
NP_001171567
NP_001984
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NT_032977
NW_001838589
NW_921795
UniProtKB:
TF_HUMAN (P13726)
Q86WH4_HUMAN (Q86WH4)
Ensembl:
ENSG00000117525
GenAtlas:
F3
GeneCard:
F3
MutDB:
F3
ALFRED:
LO003764U
HuGE:
F3
Comparative Toxicogenomics Database:
2152
ModBase:
P13726
HumanCyc Gene:
HS04145
HGNC:
3541

Common Searches